News Focus
News Focus
icon url

randychub

09/30/25 9:54 PM

#5511 RE: DewDiligence #5510

Thanks for saying what I have been thinking.   Why not wait and get a better deal.   
icon url

go seek

09/30/25 10:08 PM

#5512 RE: DewDiligence #5510

At this point, we may see $8 again, hopefully not. Apparently ENTA still needs to / and wants to make a deal. I expect they are close to a deal and this raise was necessary to make ‘the deal’ happen and move the RSV program forward. At the same time they wanted more financial flexibility for all operations. The alternative… possibly no RSV deal and tight finances.
> I am in the camp that believes, on days like yesterday, it is prudent to take some profits.
icon url

dewophile

09/30/25 10:37 PM

#5513 RE: DewDiligence #5510

I’m now very curious the strategy moving forward. Before the raise I thought it was simply to farm out RSV and focus on immunology. Now I’m not sure. The HR data gives high confidence for a successful phase 3 IMO but it’s going to take at least 2 years to enroll. So they might now be looking to co-develop amd want resources to opt into 323 w a partner as well. Of course this could just be leverage for a straight up outlicensing as well but the direction the company now takes is more up in the air I think
icon url

alertmeipp

10/01/25 12:07 AM

#5515 RE: DewDiligence #5510

>>This is simply a boneheaded deal, IMO.

Because of the discount I assume? or the 20% additional dilution from original PR? both?

I can see the raise, but such a large discount just odd.
icon url

DC15

10/01/25 9:44 AM

#5524 RE: DewDiligence #5510

It may feel like the person responsible for the shelf offering and its execution was committing a sick joke but hopefully this will soon be understood as a minor itch that needed to be scratched. Time to pay the rent on that beautiful laboratory and office space.
icon url

DewDiligence

10/04/25 3:27 PM

#5586 RE: DewDiligence #5510

Upon further contemplation I can come up with only one plausible explanation for why ENTA rushed into the capital raise on 9/30/25: that 9/30/25/25 was the last day of the fiscal year.

When ENTA’s 10-K report comes out in late November, I expect to read that raising capital during FY2025 was a component of the formula that determines the bonuses to be granted to ENTA’s executive officers. C’est la vie.

I’m now done discussing this topic. As noted at the bottom of #msg-176762192, I'm going to hold all of my shares because the upside continues to be colossal.